DNA damage in bipolar disorder.

Department of Biochemistry, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul. Rua Ramiro Barcelos, 2600/Anexo. Zip code: 90035-003. Porto Alegre, Brazil.
Psychiatry Research (Impact Factor: 2.68). 10/2007; 153(1):27-32. DOI: 10.1016/j.psychres.2006.03.025
Source: PubMed

ABSTRACT Bipolar disorder (BD) is a prevalent, chronic, severe, and highly disabling psychiatric disorder that is associated with increased morbidity and mortality due to general medical conditions. There is an emerging body of evidence correlating chronic medical conditions with DNA damage. The present study was designed to assess DNA damage in BD patients using the comet assay (CA). Thirty-two bipolar-I outpatients diagnosed using the Structured Clinical Interview for DSM-IV were matched with 32 healthy volunteers. Manic and depressive symptoms were assessed using the Young Mania Rating Scale and the Hamilton Depression Rating Scale, respectively. Peripheral blood samples were collected and a standard protocol for CA preparation and analysis was performed. The present study showed that BD outpatients present an increased frequency of DNA damage relative to controls. The frequency of DNA damage correlated with the severity of symptoms of depression and mania.


Available from: Mirian Salvador, Jun 02, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lethal and sublethal responses related to different phases of metabolism (phases I and II enzymatic activities), neurotoxicity (acetylcholinesterase activity), oxidative stress (lipid peroxidation and antioxidant enzyme activities), and genetic damage (DNA strand breaks) were analysed to assess the possible adverse effects of pharmaceuticals bound to marine sediments. The crustacean amphipod Ampelisca brevicornis was chosen as the bioindicator species. Organisms were exposed for 10 days to sediment spiked with pharmaceutical compounds frequently used and previously detected in the environment: carbamazepine (CBZ), ibuprofen (IBP), fluoxetine (FX), 17α-ethynylestradiol (EE2), propranolol (PRO), and caffeine (CAF). Short-term bioassay to evaluate amphipod mortality was recommended to assess pollution by CBZ, FX, and PRO. IBP and PRO were metabolized by phases I and II detoxification enzymatic activities. Oxidative stress was caused by PRO and CAF. Contrary to expected results, DNA damage (strand breaks) decreased after the exposure of amphipods to sediment spiked with IBP, FX, EE2, PRO, and CAF (including environmental concentrations). FX was neurotoxic to amphipods. The battery of biomarkers tested allowed the assessment of bioavailability, oxidative stress, genotoxicity, and neurotoxicity of the pharmaceuticals analysed. The results of this study suggested that pharmaceutical products at concentrations currently found in the environment might cause a wide variety of adverse effects (based on laboratory studies). The results obtained here are useful for environmental risk assessment of marine sediments contaminated by pharmaceuticals. Nevertheless, more research is needed using field-based marine sediments.
    Archives of Environmental Contamination and Toxicology 09/2014; 68(2). DOI:10.1007/s00244-014-0080-0 · 1.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oxidative stress may contribute to the pathophysiology of bipolar disorder. The aim of this study was to investigate the serum levels or activities of oxidative stress markers in bipolar patients in a manic phase, and evaluate the changes in superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), thiobarbituric acid reactive substances (TBARS), protein carbonyl content (PCC) and 8-hydroxy 2′-deoxyguanosine after treatment (8-OHdG).Methods We consecutively enrolled 23 bipolar inpatients in a manic phase and 40 healthy subjects. Serum oxidative stress markers were measured with assay kits. All patients were evaluated by examining the correlation between oxidative stress markers and Young Mania Rating Scale (YMRS) scores.ResultsThe serum TBARS levels in bipolar patients in a manic phase were significantly higher than those of healthy subjects (p=0.006), and serum GPx activity was significant lower than that of healthy subjects (p<0.05). The YMRS scores had a significantly positive association with CAT activity and PCC levels (p<0.05) and a negative association with GPx activity (p<0.05). Twenty bipolar patients were followed up, and their oxidative stress markers were measured at the end of treatment. We found significantly decreased changes in TBARS levels only in bipolar manic patients after treatment (p=0.019).LimitationOur sample size was limited.Conclusion Our results suggest that serum TBARS levels might be a state biomarker of oxidative stress in bipolar patients in a manic phase and after treatment. In addition, GPx deficit might be a trait biomarker of severity of mania.
    Journal of Affective Disorders 11/2014; 173. DOI:10.1016/j.jad.2014.10.045 · 3.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background It has been suggested that depressed persons have increased oxidative stress and decreased anti-oxidant defences. 8-Hydroxy-2′-deoxyguanosine (8-OHdG) and F2-isoprostanes, measures of oxidative DNA and lipid damage respectively, are among the most reliable oxidative stress markers, but studies on their association with depression show conflicting results. This meta-analysis quantifies the association between depression and these markers and explores factors that may explain inconsistencies in the results. Methods A systematic literature search was conducted in PubMed, EMBASE and PsycINFO. Studies assessing the association of 8-OHdG or F2-isoprostanes with elevated depressive symptoms, major depressive disorder (MDD) or bipolar disorder (BD) were pooled in two random-effect models. Results The pooled effect size (Hedges’ g) for the association of depression with oxidative stress was 0.31 (p = 0.01, I2 = 75%) for 8-OHdG (10 studies, 1308 subjects) and 0.48 (p = 0.001, I2 = 73%) for F2-isoprostanes (8 studies, 2471 subjects), indicating that both markers are increased in depression. There was no indication of publication bias for either marker. The F2-isoprostane results did not differ by type of depression, biological specimen, laboratory method or quality, however subgroup analyses in the 8-OHdG studies showed significantly stronger associations in plasma/serum vs. urine samples (p < 0.01), in measurements performed with immuno-assay vs. chromatography–mass spectrometry (p < 0.01) and weaker associations in high quality studies vs. low (p = 0.02). Conclusion This meta-analysis finds that oxidative stress, as measured by 8-OHdG and F2-isoprostanes, is increased in depression. Larger-scale studies are needed to extend the evidence on oxidative stress in depression, and examine the potential impact of treatment.
    Psychoneuroendocrinology 01/2015; 51:164–175. DOI:10.1016/j.psyneuen.2014.09.025 · 5.59 Impact Factor